Considering these data as whole, we found that a significant fraction of ovarian cancers that have been analyzed display an aberrant expression of cyclins, CDKs and/or CDKI (Table 2), supporting the hypothesis that these tumors could be potentially sensitive to CDK4/6i. This evidence concerns the gene CDK4 and ovarian carcinoma.